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1. Introduction  
No long-term effective treatments are currently available for brain neurological disorders 
such as focal and global cerebral ischemia, traumatic brain injury (TBI) and 
neurodegenerative disorders. Current treatments are primarily focused on limiting the 
damage and slowing the degeneration and, most of them are only symptomatic while 
function restoration is rarely achieved. This underlies the need for alternative therapies such 
as brain cell therapy that allows functional replacement of missing or damaged neurons by 
transplanting cells that may differentiate into the desired phenotype and integrate the host 
parenchyma, or alternatively rescue the affected neuronal population. Due to the high cell 
death that occurs during neurodegenerative processes, brain neurological disorders are an 
ideal target for cell-based therapies. Several teams tried to prevent the loss of neurons or to 
replace them, using neuronal precursors and lately, since stem cell discovery, embryonic 
stem (ES) cells, adult stem cells, tissue-derived stem cells or more recently induced 
pluripotent stem (iPS) cells (for review see (Abeliovich & Doege, 2009; Joyce et al., 2010; 
Chen & Xiao, 2011; Loewenbruck & Storch, 2011). These studies demonstrated the potential 
of cell therapy to repair the injured brain even if poor survival of grafted cells was reported 
(Brundin et al., 1985; Schierle et al., 1999; Brundin et al., 2000; Isacson et al., 2003; Olanow et 
al., 2003). In this book chapter, brain cell therapy studies performed with adult non-
transformed cells that, by nature, allow the use of autologous tissues for transplantation and 
overcome the immunological, availability, as well as ethical concerns will be reported.  
It is important to bear in mind that, for organs with a higher level of complexity such as the 
brain, cell therapy remains a challenging task. Fortunately, relatively recent medical, 
biological and technological advances in tissue engineering approaches allow functional 
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tissue and organ recovery by using the appropriate combination of three fundamental 
“tools” known as the tissue engineering triad: cells, engineered materials and signalling 
molecules (essentially growth factors). In practice, this is translated into a great versatility 
of delivery systems, which mimic the natural repairing environment of the brain tissue, 
creating tuneable and customized spatio-temporal gradients of signals guiding tissue 
regeneration. Bioactive scaffolds are likely to reinforce the success of cell replacement 
therapies by providing a microenvironment that facilitates the survival, proliferation, 
differentiation, and connectivity of transplanted and/or endogenous cells 
(Pettikiriarachchi et al., 2010). However, delivery of cells with scaffolds to the damaged 
brain still remains challenging due to practical limitations of delivery. The second part of 
this book chapter will provide an overview of what solutions tissue engineering may 
provide for adult cell therapy of the brain. Since the brain is a functionally complex organ, 
cell growth and differentiation alone are not enough in order to achieve its functional 
recovery. The correct re-establishment of the axonal connections and neuronal circuits is 
also necessary. In general, scaffolds for brain therapy should meet several essential 
requirements like being biocompatible, biodegradable, immunologically inert and able to 
support neurite outgrowth. The most common materials, fabrication methods and 
desirable properties of biomaterials used for brain protection repair and regeneration will 
be presented. 
Brain tissue engineering has several limitations and many unanswered questions or 
concerns should be addressed before reaching the clinic. Moreover, with the current 
workflow, it takes a long time to select an effective brain tissue engineering strategy to 
translate into clinical studies. Additionally, recent developments in understanding the basic 
biology of brain tissue formation in physiological and pathological conditions have resulted 
in an explosion in the numbers of tissue engineering products that could be potential 
candidates for treating brain disorders. Screening platforms that bridge the gap between 
conventional tissue culture and animal models would help to improve understanding of 
cell-based therapies and optimize central nervous system (CNS) tissue engineering. In this 
regard, the usefulness of 3D brain organotypic cultures in CNS research as well as in the 
drug discovery process will be discussed in this book chapter. 
2. Adult cell therapy for brain neuronal damages 
2.1 Adult cells for cerebral ischemia and traumatic brain injury therapy 
2.1.1 Adult stem cell therapy 
Mesenchymal stem cells (MSCs) are the most widely investigated adult stem cells for brain 
cell therapy of cerebral ischemia and TBI (Table 1). Various animal models of ischemia have 
been used to investigate the therapeutic effects of MSCs on the lesioned brain and in all 
these models, bone marrow-derived MSCs resulted in an increased survival of neurons and 
most of the time in an improved cognitive function of the animals (reviewed in (van 
Velthoven et al. 2009)). In addition, MSCs have been described to reduce the thickness of the 
scar walls (Li et al., 2005) and may also favour angiogenesis (Chen et al., 2003; Chopp et al., 
2008) as well as synaptogenesis (Chen & Chopp, 2006). Functional improvements may be 
observed whatever the implantation route, intravenously or intracerebrally, even if 
reduction in infarct volume is not always observed (Li et al., 2000). This underlines the 
capacity of MSCs to migrate towards lesions, as was already observed by other groups 
www.intechopen.com
Advances in the Combined Use of Adult Cell Therapy  
and Scaffolds for Brain Tissue Engineering 
 
381 
(Chen et al., 2001) after IV injection, or after intracerebral graft in a lesioned rat brain 
(Sykova & Jendelova, 2007; Delcroix et al., 2009). Noteworthy, in situ neural or neuronal 
differentiation of transplanted MSCs has been described in several studies. For example, 
systemic or intracarotid artery administration of MSCs in rat models of ischemia improve 
neurogenesis and functional recovery, with the detection of neuronal or glial markers 
expressed by a fraction of MSCs in the brain (van Velthoven et al., 2009; Li et al., 2002; 
Esneault et al., 2008; Perasso et al., 2011). However, due to the low grafted cell survival and 
neural/neuronal differentiation, neurological benefits are often assumed to mainly derive 
from the increased production of growth factors and other paracrine factors from MSCs in 
the ischemic tissue (England, 2009; Yarygin et al., 2009). Factors secreted by the ischemic 
brain itself, such as vascular endothelial growth factor (VEGF) and erythropoietin (EPO), are 
also thought to play a major role in brain protection from ischemia (Tang et al., 2006). MSCs 
combined with growth factors also provided functional effects and in some cases reduced 
the lesion volume, the number of apoptotic cells within the ischemic lesion and stimulated 
host repair responses as recruitment of host progenitor cells (Esneault et al., 2008; 
Rahnemai-Azar et al., 2011; van Velthoven et al., 2009). Modulation of inflammatory and 
immune response or production of neuroprotective chemokines such as fractalkine and 
monocyte chemoattractant protein-1 (MCP-1) by MSCs are others mechanisms that may be 
involved in neuronal protection during ischemia (Re & Przedborski, 2006; Ohtaki et al., 
2008; Madrigal et al., 2009; Garbayo et al., 2011). Recruitment of host progenitor cells may 
also contribute to MSC-induced repair processes in response to chemokines [growth-related 
oncogene (GRO), MCP-1] secreted by the implanted cells (Rahnemai-Azar et al., 2011; 
Gordon et al., 2009). After a first clinical trial that underwent criticisms a few years ago 
(Bang et al., 2005; De Keyser, 2005), there is a growing number of phase I-II clinical trials to 
evaluate the safety and efficacy of MSCs or CD34+ cells delivered either by arterial infusion, 
IV or intracranial injection in the context of stroke (see clinicaltrials.gov for up to date 
informations).  Moreover, two consecutive meetings have been held recently named the 
Stem cell Therapies as an Emerging Paradigm in Stroke (STEPS I & II), in order to provide 
guidelines for preclinical and clinical studies leading to the successful development of cell 
therapy for stroke (Broderick, 2009; Savitz et al. 2011).  
In the context of TBI, MSCs may also improve functional benefits whatever the injection 
route. However, a maximum of 10 % implanted MSCs may transdifferentiate into neuronal 
cells in vivo so that, again, this mechanism was assumed not to be solely responsible for the 
functional benefits observed in TBI animal models (Li & Chopp, 2009). Growth factor 
production by MSCs stimulated by the lesioned brain (Chen et al., 2002) was certainly the 
main mechanism leading to functional recovery by promoting glial, neuronal and blood 
vascular remodelling (Li & Chopp, 2009; Richardson et al., 2007). However, despite the 
benefits obtained using this approach, no significant changes in the lesion volume were 
observed, a problem that tissue engineering alternatives may resolve (see section 3 of this 
chapter).  Concerning adult neural stem cells (NSCs), very few studies were performed in 
the context of stroke, and none for TBI. It is however interesting to note that a fraction of 
adult NSCs, either derived from rat hippocampus (Zhang et al., 2011) or from human 
wisdom teeth (Yang, Chen et al., 2009),  survived within the brain after transplantation and 
led to significant improvements in stroke. Another population of CD31-/CD146- cells 
isolated from dental pulp has also been used in stroke rat models, leading to migration and 
differentiation of the endogenous neuronal progenitor cells as well as vasculogenesis 
(Sugiyama et al., 2011).  
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Cells Origins Recipients Scaffolds Benefits References
Mouse MCAO mouse model Functional benefits but no reduction in infarct volume Li, Chopp et al. 2000
Rat MCAO rat model IV transplantat ion: migration toward the lesion Chen, Li et al. 2001
Human MCAO rat model
IV transplantat ion: importance of growth factor increase in the 
ischemic tissue
Li, Chen et al. 2002
Rat MCAO rat model
IV transplantat ion in combination with EPO: functional recovery 
and neurogenesis                                                                            
A fraction of MSCs with neuronal and glial markers
Esneault, Pacary et al. 2008
Rat MCAO rat model IV transplantat ion: reduced thickness of the scar walls Li, Chen et al. 2005
Human MCAO rat model IV transplantat ion: promotion of angiogenesis Chen, Zhang et al. 2003
Human tCCAO mouse model Modulation of inflammatory and immune responses Ohtaki, Ylostalo et al. 2008
Mouse 2VO rat model IV transplantat ion: increased number of pyramidal CA1 neurons Perasso, Cogo et al. 2011
Human ACA rat model
FN-coated PLGA 
microspheres
Neuroprotect ion of CA1 hippocampal neurons with MIAMI cells: 
neuroprotect ion enhanced with microspheres 
Garbayo, Curtis et al. 2011
Human TBI rat model Collagen cylinder 
Scaffolds improved spatial learning, sensorimotor function & 
reduced the lesion volume
Lu, Mahmood et al. 2007
Human TBI rat model Collagen cylinder 
Delayed transplantation: increased angiogenesis in the injured 
cortex & transcallosal fiber length 
Xiong, Qu et al. 2009
Human TBI mouse model Collagen cylinder 
Scaffolds improved spatial learning, reduced lesion volume & 
increased vascular density
Qu, Xiong et al. 2009
Human
Human            
(autologous, stroke)
Proof of safety for MSCs use in human Bang, Lee et al. 2005
Human
From teeth
MCAO rat model Functional benefits Yang, Chen et al. 2009
Rat 
hippocampi 
MCAO rat model
Amelioration of neurological deficits
Reduced total infarct volume
Zhang, Jin et al. 2011
CD31-
/CD146- 
progenitor 
cells 
Pig
Teeth-
derived
MCAO rat model
Migration and differentiation of the endogenous neuronal 
progenitor cells
Vasculogenesis
Sugiyama, Iohara et al. 2011
Mouse
Embryonic 
fibroblast-
derived
MCAO rat model Fibrin glue
Sub-dural injection reduced the infarct size compared to iPS cells 
directly injected in the parenchyma 
Functional improvements and no teratoma when sub-dural 
inject ion with f ibrin glue is used
Chen, Chang et al. 2011
Human 
Fibroblast-
derived
MCAO rat model
Migration of the cells towards injured brain area
In situ  neuronal differentiation of iPS cells
Improved sensorimotor funct ion 4-16 days after graft ing
Jiang, Lv et al. 2011
iPS cells
Abbreviations: ACA: asphyxial cardiac arrest; EPO: erythropoietin; FN: fibronectin; iPS: induced pluripotent stem; IV: intravenous; MCAO: middle cerebral artery 
occlusion; MIAMI: marrow isolated adult multilineage inducible; MSC: mesenchymal stem cell; NSC: neural stem cell; tCCAO: transient common carotid artery 
occlusion, UPDRS: unified Parkinson's disease rating scale.
NSC
MSC
 
Table 1. Adult and iPS cell therapies for cerebral ischemia and TBI 
2.1.2 Adult derived pluripotent stem cell therapy  
A growing interest is now observed in the scientific community for the iPS cells. These 
“embryonic-like” cells were primarily derived from adult fibroblasts by the expression of 
transcription factors (a combination of 4 factors within c-Myc, KLF4, LIN28, Nanog, Oct3/4 
and Sox2) (Takahashi et al., 2007; Yu et al., 2007). Several applications are currently 
envisioned for these pluripotent cells, which share the same potential than ES cells, without 
the associated ethical problems. In addition to their applications for drug discovery and 
toxicity testing (Laustriat et al., 2010) these cells may be helpful for complex disease 
understanding. They are also attractive for cell therapy studies, due to the possibility to 
obtain a large amount of cells from various lineages and to perform autologous grafts. iPS 
have now been derived from several types of adult tissues, with variable efficiency, and 
always using refined protocols to avoid permanent genomic integration and the use of 
lentiviruses for transducing the cells (Okita et al., 2011; Narsinh, et al., 2011; Lee et al., 2009; 
Gonzalez et al., 2009; Zhou et al., 2009; Page et al., 2009; Yu et al., 2009). Indeed, uses of 
viral-based protocols may be at the origins of tumour formation and may also lead to 
further difficulties to differentiate the cells toward a given phenotype (Yu et al., 2009). The 
propensity of iPS to form teratomas may also be related to the tissue of origin of the cells 
(Miura et al., 2009). Despite their great interest, one has to keep in mind that further 
developments are still required to fully understand their reprogramming process 
(Nakagawa & Yamanaka, 2011) in order to provide a safe cell therapeutic product for the 
Garbayo, Raval et al. 2011 
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clinic (Pera, 2011). In the context of ischemic stroke, an interesting study describes the use of 
iPS-derived neurons and astrocytes directly injected in the damaged cortex of a stroke 
animal model (Chen et al., 2011), which resulted in a reduced ischemic size with functional 
improvements. Another study describes the in situ migration and differentiation of human 
iPS cells in a similar context, with an improved sensorimotor function of the animals 4-16 
days after grafting (Jiang et al. 2011). 
2.2 Adult cells for neurodegenerative disorder therapy 
Huntington’s and Parkinson’s diseases (HD and PD respectively) have been widely studied 
in cell therapy programs due to the relatively small area affected by the diseases, 
particularly at early stages (see for reviews (Lindvall & Kokaia, 2009; Loewenbruck & 
Storch, 2011)). In opposition, Alzheimer’s disease (AD) would be more complex to treat due 
to the multiple sites of the brain affected in this disease. Moreover, no tissue engineering 
strategies have yet been described for AD so that we will only focus on HD and PD in the 
following (Table 2).  
2.2.1 Adult cell therapy 
An increasing number of studies performed with foetal tissue, ES cells or NSC grafts, mostly 
in quinolinic acid (QA)-induced animal models of the disease (Clelland et al., 2008) gave 
successful results leading to clinical trials with foetal-derived cells. However, cell therapy 
for HD, an incurable disease, is still not widely available in clinic due to ethical, logistical or 
safety concerns (Kelly et al., 2009). Adult cells have only been used in early studies with 
Sertoli cell grafts that protected the lesioned area in an animal model of HD; effects that may 
result from Sertoli cells trophic and anti-inflammatory potentials (Emerich, 2004). 
One of the first cell therapy strategies to treat PD has been performed with adult cell types 
synthesizing dopamine or its precursor L-DOPA, in order to replenish the striatum level of 
dopamine (for review (Drucker-Colin & Verdugo-Diaz, 2004; Fernandez-Espejo et al., 2005). 
Autologous adrenal medulla tissue were grafted in the caudate nucleus of 2 young PD 
patients, but observed functional improvements  were transitory and mainly due to trophic 
effects as only 1 % of the cells synthesized dopamine (Madrazo et al., 1987). Most 
importantly, very few cells were detected 1 or 2 years after transplantation (Hurtig et al., 
1989). Other studies were performed using cultured chromaffin cell suspensions, but few 
surviving cells in long term studies did not validate this approach (Drucker-Colin et al., 
1999). Human retinal pigment epithelium (hRPE) cells derived from the inner layer of the 
neural retina are isolated from human eye bank for transplantation purposes (reviewed in 
(Stover & Watts, 2008)). hRPE cells may be expanded, present a tyroxine hydroxylase 
activity (Pawelek & Korner, 1982), and produce L-DOPA, which is synthesized as a melanin 
precursor, so that these cells may supplement the oral administration of L-DOPA in situ. 
Moreover, it has been proposed that hRPE cells may be immune-privileged after 
transplantation due to their expression of Fas-ligand (Griffith et al., 1995; Jorgensen et al., 
1998). 
2.2.2 Adult stem cell therapy 
Adult stem cells are expected to better differentiate and integrate the host brain compared to 
adult non-stem cells and are therefore widely investigated for their therapeutic potential in 
the context of neurodegenerative disorders. Whole bone marrow cells [i.e. hematopoietic 
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stem cells (HSCs) & MSCs] implanted into the bilateral lesioned striatum of HD rat models, 
reversed functional deficits such as working memory (Lescaudron et al., 2003) even if the 
cell population responsible for the beneficial effects remained unknown. Noteworthy, 
autologous grafts may not be an appropriate strategy for the treatment of HD as 
transplanted cells would also carry the mutant huntingtin gene responsible for the disease. 
More recently, transplantation of MSCs, either intracerebrally or intravenously, resulted in a 
decreased atrophy of lesioned rat striatum (Amin et al., 2008) and in some functional 
benefits (Edalatmanesh et al., 2009) even though only a fraction of cells (1 %) expressed 
neural phenotypes. Thus, it was suggested that MSCs, by producing growth factors, 
allowed surviving cells within the caudate nucleus to function more efficiently and to 
facilitate other compensatory responses (Dunbar et al., 2006). In this regard, another study 
demonstrated the importance of factors such as stem cell factor (SCF), produced in situ in 
the lesioned striatum, to promote the migration and engraftment of MSCs via SCF 
receptor c-kit (Bantubungi et al., 2008).  
In the context of PD, several teams, including ours, reported the neuronal differentiation of 
human MSCs toward a dopaminergic phenotype in vitro, indicating that these cells may 
constitute an alternative dopamine secreting source of cells (Trzaska & Rameshwar, 2011; 
Barzilay et al., 2008; Trzaska et al., 2007; Tatard et al., 2007). An interesting study also 
reported no major differences between MSCs from normal patients compared to MSCs 
isolated from parkinsonian patients, which may be induced to produce up to 30 % of 
dopaminergic neurons in vitro (Zhang et al., 2008). Human MSCs, pre-induced towards a 
neuronal phenotype and transplanted in the totally dopaminergic deafferented striatum of 
rats, led to an improved functional recovery for up to 4 months compared to naïve hMSCs 
(Levy et al., 2008). A similar recovery has been observed in a rat partial lesion model of PD, 
in which dopaminergic fibers are spared in the striatum (Bouchez et al., 2008). Moreover, 
microdialysis demonstrated that part of the striatal pool of dopamine was restored upon 
MSCs transplantation. Naïve hMSCs or a subpopulation of hMSC pre-treated with 
epidermal growth factor (EGF) and basic fibroblast growth factor (bFGF) also led to an 
efficient recovery after partial lesions, suggesting a paracrine restorative effect by MSCs. 
Indeed, hMSCs, that migrate toward lesions (Hellmann et al., 2006; Sadan et al., 2009; 
Delcroix et al., 2011) may induce a protective or restorative effect on the remaining neurons 
within the host brain, due to the secretion of a large panel of neurotrophic factors, including 
brain-derived neurotrophic factor (BDNF) and glial cell line-derived neurotrophic factor 
(GDNF), which may also enhance endogenous neurogenesis (Levy et al., 2008; McCoy et al., 
2008; Bahat-Stroomza et al., 2009; Sadan et al., 2009). MSCs may also modulate the host 
response to the lesion (Kim et al., 2008) and probably ultimately replace functional cells 
within the host brain as a few MSCs with neuronal-like morphology and markers were 
observed in a total lesion model (Levy et al., 2008). We are therefore starting to better 
understand the mechanisms of action of these cells in the context of PD, while other teams 
try, with interesting results, to find new ways to deliver the cells to the brain. Indeed 
recently, a non invasive intranasal delivery of MSC in an animal model of PD, with 
significant improvements in the functional outcome of the animals was reported (Danielyan 
et al., 2011). The growing amount of MSC therapy studies for PD is starting to set the 
ground for pre-clinical studies, and a trial is already underway to evaluate the safety and 
efficiency of intrastriatal grafts of autologous MSCs to treat PD (Jaslok Hospital and 
Research Centre, India, sources clinicaltrials.gov).  
www.intechopen.com
Advances in the Combined Use of Adult Cell Therapy  
and Scaffolds for Brain Tissue Engineering 
 
385 
NSCs isolated from the adult brain have been evaluated for the treatment of PD and HD due 
to their potential to differentiate into neurons in vivo (Lois & Alvarez-Buylla, 1993), despite 
the problems encountered for their isolation. A study reported the transplantation of NSCs 
from adult rat SVZ in a rat model of HD, with NSC survival up to 8 weeks after grafting and 
migration throughout the brain. To a larger extent than MSCs, up to 15 % of adult NSCs 
differentiated into mature neurons with specific markers of striatal medium spiny projection 
neurons and interneurons (Vazey et al., 2006). In addition, priming these cells with lithium 
chloride resulted in an even further improved functional outcome of the grafted animals 
(Vazey & Connor, 2011). To treat PD, a clinical trial has been performed with adult NSCs 
(reviewed in (Arias-Carrion & Yuan, 2009)) and gave interesting proof of concept for the 
autologous use of these cells. NSCs were isolated from the patient’s brain during the 
insertion of a thalamic stimulator and, after expansion and differentiation, a total of 6 
millions cells, and among them GABAergic and dopaminergic cells, were grafted 9 months 
later into the patient’s post-commissural putamen. An improvement in the Unified 
Parkinson's Disease Rating Scale (UPDRS) score was observed over the next 36 months, 
although results returned to baseline at 5 years post-operation (Levesque, 2009).  
2.2.3 Adult cell-derived pluripotent stem cell therapy 
As for several other disorders, iPS cell have been evaluated for PD cell therapy (Table 2). 
Dopaminergic neurons have efficiently been derived from iPS cells, and those cells have led 
to functional recovery in an animal model of PD (Wernig et al., 2008; Swistowski et al., 
2010). In addition, it was recently demonstrated that iPS derived from patients suffering 
from idiopatic PD, after dopaminergic differentiation in vitro, led to an efficient functional 
recovery of the grafted animals (Hargus et al., 2010). 
To conclude this section, it appears clearly that MSCs were, and still are, the most widely 
investigated adult cells for brain cell therapy. However, their neuronal differentiation potential 
remains very low or uncertain after transplantation, explaining the scientific interest of the 
recently discovered iPS cells. In addition, the poor cell survival and engraftment observed 
when using chromaffin cells, hRPE cells, MSCs and in general all kinds of transplanted cells, 
has called into question the efficacy of a cell therapy procedure. These issues may now be 
acknowledged by tissue engineering approaches, discussed in the following section.  
3. Combined use of adult stem cells and scaffolds for cell delivery and 
regeneration of CNS disorders 
It is now widely admitted that cell survival, differentiation, and more generally behaviour of 
cells in vivo may be greatly enhanced using adequate biomaterial supports. These 
supportive elements, called scaffolds, may be of various compositions and shapes and may 
improve cell behaviour due to the 3D environment as well as to the mechanical and 
signalling cues they provide to transplanted cells. In this regard, scaffolds may for example 
stimulate cell survival. These types of tissue engineering strategies for brain cell therapy 
have been primarily developed with neuronal cell lines (PC12 cells) or with cultured dorsal 
root ganglion neurons and foetal NSCs due to their availability, ease of expansion and their 
natural ability to integrate and differentiate within the brain. Benefits gained using these 
tissue engineering approaches are now being translated to adult cells such as MSCs in order 
to improve their survival, to guide their differentiation and integration within the host 
brain. In the following section, we describe the properties required for a scaffold in tissue 
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engineering applications within the brain, before reviewing the strategies used to improve 
brain cell therapy by combination with a tissue engineering approach. Improvement of 
classical scaffolds by means of a biomimetic approach as well as a novel strategy currently 
developed in our laboratory, the Pharmacologically Active Microcarriers (PAMs), will be 
presented. 
 
Cells Origins Recipients Scaffolds Benefits References
Sertoli 3-NP model Possible modulation of local inf lammation Emerich 2004
Choroid 
plexus
Rat QA rat model
Alginate 
microcapsules
Selective neuroprotection, no evidence for sparing of striatal 
neurons
Borlongan, Thanos et al.  2008
HSC+MSC Rat QA rat model Reduction of working memory deficits Lescaudron, Unni et al.  2003
Rat QA rat model Decreased striatal atrophy Amin, Reza et al.  2008
Rat QA rat model Attraction of MSCs by SCF production in the striatum Bantubungi, Blum et al.  2008
Rat QA rat model IV transplantation: improved motor & cognit ive performance Edalatmanesh, Matin et al.  2009
Rat QA rat model
Survival at 8 weeks, migration & 15 % of cells differentiated in 
mature neurons with marker of striatal medium spiny neurons 
Vazey, Chen et al.  2006
Rat QA rat model
Lithium chloride priming of the NSCs resulted in accelerated 
funct ional outcome of the grafted animals
Increased formation of projections from newly formed neurons in 
the damaged host striatum to the globus pallidus
Vazey and Connor 2011
Human Human (autologous) Functional improvements observed up to 10 months Madrazo, Drucker-Colin et al. 1987
Human Human (autologous) No cell detected after 1-2 years Hurtig, Joyce et al. 1989
Rat
6-OHDA rat model 
(unilateral)
Cytodex®       
Glass beads
Increased survival and functional benefits (8 months) Cherksey, Sapirstein et al.  1996
Rat
6-OHDA rat model 
(unilateral)
Cytodex®       
Glass beads
Increased survival and functional benefits (12 months) Borlongan, Saporta et al. 1998
Human Human Improved dopamine production with in vitro differentiation Drucker-Colin, Verdugo-Diaz et al. 1999
Human
6-OHDA rat model (uni 
& bilateral)
Gelatine 
microcarriers 
(Spheramine®)
Functional recovery with chronic inflammation at late time-point Cepeda, Flores et al. 2007
Human MPTP primate model
Gelatine 
microcarriers 
(Spheramine®)
Long term functional improvements an cell survival                      
(18 months)                                                                                     
No immunosuppression required
Doudet, Cornfeldt et al.  2004
Human Human
Gelatine 
microcarriers 
(Spheramine®)
Open-label study: good tolerability, sustained motor clinical 
improvement up to 6 months after grafting                                      
Bakay, Raiser et al. 2004
Human Human
Gelatine 
microcarriers 
(Spheramine®)
Analysis of the brain of a patient who underwent the last trial 
performed with Spheramine® (phase II double-blind, randomized, 
mult icenter, placebo-controlled clinical) with no significant 
funct ional improvements
6 months after graf ting, only 0.036 % of surviving cells
Farag, Vinters et al. 2009
Rat
6-OHDA rat model 
(unilateral & part ial)
Adipose tissue-derived MSCs secreting BDNF, GDNF & NGF        
Functional recovery after transplantation in SN but no neuronal 
differentiation in vivo
McCoy, Martinez et al.  2008
Human
6-OHDA rat model 
(unilateral & part ial)
Induction of MSCs to secrete GDNF & BDNF                               
Transplanted on the day of lesion, MSCs migrated toward the 
lesioned striatum and had a regenerative effect
Sadan, Bahat-Stromza et al. 2009
Human
6-OHDA rat model 
(unilateral & total)
Improved functional recovery with differentiated cells                 
(TH expression and DOPA secretion)
Levy, Bahat-Stroomza et al. 2008
Human
6-OHDA rat model 
(unilateral & part ial)
Trophic, restorative effect of MSCs Bouchez, Sensebe et al. 2008
Human
6-OHDA rat model 
(unilateral & part ial)
PAMs                   
with LM surface & 
releasing NT3
With PAMs: 
Increased MIAMI cells survival and differentiation in vivo 
Neuroprotection, neuroreparation of the nigrostriatal pathway
Functional recovery
Delcroix, Garbayo et al. 2011
MSC Rat
6-OHDA rat model 
(unilateral & total)
Innovative intranasal delivery
Migration of the cells throughout the brain
24 % of cells survival 4.5 months after grafting
Improvement of motor function of the Parkinsonian
forepaw
Danielyan, Schafer et al.  2011
Adult NSC Human
Human (autologous) 
Cort ical and sub-cortical 
tissue-derived
After expansion and differentiation in vitro , NSCs improved 
UPDRS score over 36 months after grafting                                    
Back to baseline 5 years post-operation
Levesque 2009
Mouse 
Fibroblast- 
derived
6-OHDA rat model 
(unilateral & part ial)
Neuronal differentiation in vivo  (TH-positive cells)
Functional improvements 4 weeks after grafting
Wernig, Zhao et al. 2008
Human 
Foetal-lung 
fibroblast-
derived
6-OHDA rat model 
(unilateral & total)
Survival of iPSC-derived dopaminergic neurons in vivo
Functional improvements 12 weeks after grafting 
Swistowski, Peng et al. 2010
PD patient
Fibroblast-
derived
6-OHDA rat model
Survival of iPS cell-derived DA neurons, with arborization
Functional improvements 16 weeks after grafting
Proof of concept for the autologous use of iPS cells 
Hargus, Cooper et al.  2010
Abbreviations: AD: Alzheimer’s disease; BDNF: brain-derived neurotrophic factor; GDNF: glial cell line derived neurotrophic factor; HD: Huntington’s disease; hRPE: human 
retinal pigment epithelium; HSC: hematopoietic stem cell; iPS: induced pluripotent stem; IV: intravenous; LM: laminin; MIAMI: marrow isolated adult multilineage inducible; 
MPTP: 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine; MSC: mesenchymal stem cell; NP: nitropropionic acid; NSC: neural stem cell; NT3: neurotrophin 3; OHDA: 
hydroxydopamine; PAMs: pharmacollogically active microcarriers; PD: Parkinson’s Disease; QA: quinolinic acid; SCF: stem cell factor; SN: substantia nigra; UPDRS: unified 
Parkinson's disease rating scale.
MSC
HD
Adult NSC 
(SVZ)
iPS cells
MSC
PD
hRPE
Adrenal 
chromaffin
 
Table 2. Adult and iPS cell therapies for neurodegenerative disorders 
Flores, Cepeda et al. 2007 
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3.1 Scaffold requirements for brain cell therapy  
Implementation of tissue engineering in combination with adult cells for brain therapy is an 
emerging field and many requirements need to be taken into account in order to produce an 
appropriate tissue engineered product. The first consideration in scaffold tailoring for brain 
is size, but scaffolds must also be fully biodegradable and biocompatible, minimizing 
macrophage and microglial reaction, without inducing neurotoxicity. Scaffolds must be 
small enough to be easily implanted into the skull cavity in discrete and precise areas of the 
brain without perturbing the brain 3D organisation as observed with 30 μm microspheres 
(Veziers et al., 2001). Moreover, small-sized scaffolds render repeated implantations possible 
by stereotaxy, with no need for open-surgery (Menei et al., 2005). In this sense, 
microstructured and nanostructured scaffolds, produced by various techniques may be used 
(reviewed in (Seidlits et al., 2008)).  
Scaffolds are based either on natural or on synthetic biomaterials used alone or in mixtures, 
providing scaffolds with different properties (see for review (Potter et al., 2008; Dalton & 
Mey, 2009). Scaffolds based on biodegradable gels encapsulating various molecules and cells 
have been studied, with e.g. polyethylene glycol (PEG) (Namba et al., 2009), diblock 
copolypeptide (Yang, Song et al., 2009) or hyaluronic acid (Wang & Spector, 2009) 
hydrogels. However, gel-based scaffold strategies most of the time require open-surgery, 
unless an in situ gelling process is used (Kim, 2009; Yang, Song et al., 2009) but no gel 
swelling must be observed. In opposition to gel-based scaffolds, particulate scaffolds, that 
may be constituted of aliphatic polyesters, including poly(lactic-co-glycolic acid) (PLGA), 
overcome this problem of delivery and have been intensively studied with embryonic cells 
and NSCs (Newman & McBurney, 2004; Bible et al., 2009). Cell-material interactions may be 
advantageously increased due to a large specific surface as with microsphere-shaped scaffolds 
or scaffolds based on nanofibrous technology (Valmikinathan et al., 2008; Cao et al., 2009).  
The adverse host cell response, such as glial scar and inflammation, occurring after scaffold 
implantation have to be minimized (see for review (Fournier et al., 2003)) therefore 
rendering the biocompatibility and biodegradability of the biomaterials a crucial parameter 
(Vert, 2009; Yang, Song et al., 2009). For example, implantation of PLGA microspheres into 
the brain does not induce a specific astrocytic or macrophage/microglia reaction, which is 
similar to the one observed after control fluid injection. Moreover, PLGA microspheres fully 
degrade into CO2 and H2O (Menei et al., 2005). Scaffolds should be able to degrade with 
time, with degradation products that may also be eliminated by the host, allowing a full 
integration of transplanted cells into the brain. This criteria was not observed for synthetic 
poly(methylidene malonate 2.1.2) microspheres implanted into rat brains even if 
biocompatibility of the intact microspheres was satisfactory (Fournier et al., 2006). It is 
interesting to note that size of particles may also affect the extent of the host response. In 
vitro, small size phagocytable hydroxyapatite particles (1-30 µm) have been shown to induce 
a strong production of the inflammatory cytokines tumor necrosis factor-alpha (TNF), 
interleukin 6 (IL6) and interleukin 10 (IL10) by human monocytes, the first cells recruited to 
the inflammation site, which may be correlated to a stronger host inflammatory response.  
On the other hand, this effect decreased for particles of more than 30 µm in diameter. 
Importantly, shape is also critical for the extent of the response, needle-shape being 
potentially more detrimental compared to spherical-shaped particles (Laquerriere et al., 
2003).  
Cell attachment to the biomaterial critically depends on its surface charges, cells being 
attracted to positive charged surface due to sialic acid residues on the cell membrane which 
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produce a net negative charge on the cell surface. Furthermore, the first step following 
implantation of a scaffold within the brain is its coverage by a non-specific layer of proteins, 
which may contribute to the inflammation process and biocompatibility problems (Fournier 
et al., 2003). Surface characteristics (charge, hydrophilicity and hydrophobicity) are therefore 
important points to consider when designing a new type of scaffold. Outer but also inner 
topography of scaffolds may affect cell behaviour once implanted into the brain. For 
example, the presence of pores and channels on the surface of synthetic poly--caprolactone 
(PCL) scaffolds may enhance host astrocytic infiltration and affect host cell migration (Wong 
et al., 2008). Moreover, access to nutrients is a critical parameter for neuronal cells, which 
require large amounts of nutrients such as glucose. Therefore, if larger implants are used, 
vascularisation is required for cell survival. In this sense, porous scaffolds, or scaffolds that 
become porous after implantation during degradation, may alleviate vascularisation 
problems.  
Finally, a very interesting study first described the effects of matrix elasticity to direct 
MSCs lineage specification. Soft type matrices mimicking brain being neurogenic while 
stiffer matrices appeared to be myogenic and furthermore osteogenic. The observed 
phenotypic specification was irreversible after several weeks in culture, therefore 
reflecting neuronal commitment of the MSCs cultivated on soft matrices (Engler et al., 
2006). Noteworthy, new data from this team seem to indicate that stiffness variation, not 
just stiffness alone, can be an important regulator of MSCs behaviour (Tse & Engler, 2011). 
Again, this underlines the importance of the choice of the biomaterial for brain tissue 
engineering. 
3.2 Scaffold design and manufacture 
The following section reviews materials and fabrication methods used in the development 
of scaffolds to enhance brain tissue regeneration. 
3.2.1 Materials 
One of the first considerations when designing a scaffold for brain tissue engineering is the 
choice of the material. Some of the aspects that should be carefully taken into account are: 1) 
if the material maintains an appropriate shape after implantation, 2) if sterilization of the 
scaffold prior to implantation is possible, 3) if the scaffold is brain biocompatible to avoid 
abnormal immune responses, 4) if the material has the appropriate degradation rate for the 
desired application and 5) the ability to provide a controlled release of the drug, in case of 
materials encapsulating a therapeutic molecule such as growth factors. Materials used in the 
development of scaffolds for brain tissue engineering can be broadly divided into 
biodegradable and non-biodegradable. Due to the transient nature of the biodegradable 
polymers, they are preferred for a brain application because they do not require surgical 
removal when the treatment is finished. Depending on their nature they can be classified in 
natural and synthetic materials. Both of them used alone or in combination have been tested 
in clinical practice. Natural materials are very interesting because they contain sites for cell 
adhesion, allowing for cell infiltration. These natural materials also exhibit similar 
properties to the soft tissues they are replacing. However, since these materials are obtained 
from natural sources, they must be purified before use and it is difficult to control the 
homogeneity of product between batches. Synthetic materials in contrast, have a known 
composition and can be designed to minimize the immune response or the degradation rate. 
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Materials (natural and synthetic) used in brain tissue engineering applications, with their 
benefits and drawbacks will be discussed below in this section.  
3.2.1.1 Natural materials  
Collagen. Collagen, one of the most common extracellular matrix (ECM) proteins, has been 
extensively used as a potential scaffold for neural tissue. Collagen is an easily accessible 
material that can be isolated from mammals, including rats, bovines and humans. One 
advantage of collagen use is that the scaffold properties can be easily varied by using 
different concentrations of collagen or by covalently modifying the cell adhesion sites. 
However, immune response could arise if cross-species transplantation is used. In the CNS 
collagen has been mainly used as  scaffolds for the treatment of TBI among others (Qu et al., 
2009; Qu et al. 2011).  
Alginate. Alginate is a natural anionic polysaccharide composed of D-mannuronic (M) and 
L-guluronic (G) residues in varying proportions. It is easily obtained from algae and can be 
cross-linked to form three dimensional scaffolds. Cross-linking and gel formation takes 
place when divalent cations, such as calcium, ionically bind carboxylic acid groups of blocks 
of guluronic residues between chains. They must undergo extensive purification to prevent 
immune responses after implantation. The main use for alginate in the area of brain tissue 
engineering is in encapsulating cells with the purpose of immune-isolation from the host. Its 
efficacy has been evaluated in models of CNS diseases like PD, stroke, ALS, spinal cord 
injury, TBI and HD among others (Orive et al., 2003; Grandoso et al., 2007; Orive et al., 2009; 
Purcell et al., 2009). 
Fibrin. Fibrin is a protein involved in the clotting of blood. Similar to collagen, fibrin 
scaffolds contain sites for cell adhesion and the scaffold properties vary depending on the 
concentration of fibrin used. Fibrin matrix has favorable features as a scaffold, that would fit 
well in the fragile CNS tissue, including biocompatibility, biodegradability, binding capacity 
to the tissue, low risk of foreign body reaction, physiological flexibility, good plasticity. 
Fibrin scaffolds have been proposed as potentially suitable vehicle for cell transplantation 
therapy and, combined with bone marrow stroma cells, have been evaluated after cortical 
injury in rats  (Yasuda et al., 2010). 
Chitosan. Chitosan is a polysaccharide industrially derived from partial deacetylation of 
chitin, the major compound of exoskeletons in crustaceans. Chitosan has been reported to be 
suitable for preparation of particulate systems (micro and nanoparticles) for brain 
application due to its good biodegradability, biocompatibility, stability and low toxicity. 
Chitosan nanoparticles coated with polysorbate 80 have been proposed for brain targeting 
(Aktas et al., 2005). However, despite its desirable characteristic, its actual use is limited 
because of its poor solubility in water.  
Other natural materials. Other examples of natural materials used in the fabrication of brain 
tissue scaffolds are dextran, fibronectin (FN), laminin (LM) or hyaluronic acid. An 
interesting approach used hyaluronic acid and collagen to develop a tridimensional 
biodegradable porous scaffold which is a sponge with an open porous structure and 
mechanical behaviour comparable to brain tissue (Wang & Spector, 2009). Dextran 
hydrogels have been investigated as drug delivery vehicles and as macroporous scaffolds 
However, the dextran non-cell-adhesive nature has limited its use in tissue engineering. To 
overcome this limitations, Levesque et al., proposed the use of macroporous scaffolds of 
methacrylated dextran (Dex-MA) copolymerized with aminoethyl methacrylate (AEMA) 
introducing primary amine groups for covalent immobilization of extracellular-matrix-
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derived peptides for axonal guidance (Levesque & Shoichet, 2006). Recently, the use of 
bioactive scaffolds generated by cryogelation of dextran or gelatine linked to LM to create 
niche-like structures that promote the differentiation of stem cells was proposed (Jurga et al. 
2011). LM and FN scaffolds have been proposed as appropriate extracellular-matrix based 
scaffolds that can be exploited to improve cell transplantation into the injured brain (Tate et 
al., 2009).  
3.2.1.2 Synthetic materials  
Poly(-hydroxyacids). Poly (α-hydroxyacids) were found to be bioabsorbable and 
biocompatible in the 1960’s. They are the most widely known, studied and used polymers 
for brain drug delivery due to its biodegradable properties, biocompatibility and the 
absence of significant toxicity (Athanasiou et al., 1996; Shive & Anderson, 1997). They 
have suitable mechanical properties for its use in scaffold fabrication. Poly (α-
hydroxyacids) are approved by the Food and Drug Administration (FDA) for its use in 
humans and have been used extensively in medicine in a variety of applications. For 
instance, more than 100 different molecules have been incorporated in PLGA 
microspheres since their first application (Menei et al., 2005). Poly (α-hydroxyacids) are 
constituted of lactic and/or glycolic acid units and degrade in vivo by nonenzymatic 
hydrolysis to lactic and glycolic acids. These can be further metabolized or excreted via 
normal physiological pathways.  
Polycaprolactone (PCL). PCL is a biodegradable polyester with minimal bio-reactivity that has 
been widely used in the biomedical field and in CNS applications in particular. PCL 
degrades very slowly by hydrolysis of ester bonds. PCL based matrices have been used for 
instances, as scaffolds for tissue regeneration after controlled cortical impact induced-TBI 
(Wong et al., 2008). 
Others. Other examples of synthetic materials used in the fabrication of brain tissue scaffolds 
are poly (glycerol sebacate) (PGS), gelatin-siloxane (GS), poly (ethylene glycol)/poly 
(ethylene oxide), poly (ethylene-co-vinyl acetate) (EVA), poly (2-hydrixyethil methacrylate) 
(pHEMA) and poly (2-hydroxyethyl methacrylate-co-methyl methacrylate) (pHEMA-
MMA). 
3.2.2 Scaffold fabrication techniques  
As brain tissue engineering progresses, the need of novel scaffold structures and fabrication 
techniques has become of great importance (See Walker et al., 2009; Subia, 2010). The most 
common scaffold production methods are revised below. After fabrication, all of these 
scaffolds are then characterized in terms of morphology, mechanical, bulk and surface 
properties. 
Phase separation. Phase separation technique is based on temperature changes to separate a 
polymeric solution in two phases. When liquid-liquid phase is separated, it is quenched to 
form two solid phases. Finally, solvent is removed and porous scaffolds are obtained. 
Biological molecules can be incorporated to the polymeric solution to obtain drug-loaded 
scaffolds. Phase separation technique can be combined with other fabrication techniques like 
leaching or prototyping to create 3D-scaffolds with controlled pore morphology.  
Particulate Leaching. Leaching is a reproducible technique to fabricate porous, sponge-like 
scaffolds with a desirable cellular structure for tissue engineering applications. Salt, wax or 
sugars known as porogens are used to create porous scaffolds. The fabrication process 
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involves casting the polymer mixed with a porogen into a desired shape, and then 
introducing a solvent that would dissolve the salt and leave the polymer intact, leaving a 
foam-like structure. 
Electrospinning. Electrospinning is an efficient method to produce nano or micro-scaffolds 
comparable to the ECM fibers natively found in the tissue. In this fabrication method, a 
polymer solution is pumped through a syringe connected to a high voltage source. As a 
droplet forms at the needle tip, electrostatic repulsions form long fibers that are collected 
onto a grounded metal plate in the form of a nanofibrous mat. Due to the simplicity of this 
method, it has received considerable attention for use in tissue engineering and more than 
200 polymers have been used for electrospinning. However, it is difficult to obtain 3D 
scaffolds with well defined pore structure and complex geometry using this technique and 
electrospinning is preferably used to produce thin 2D sheets. 
Rapid prototyping. Rapid prototyping describes different manufacturing processes that allow 
automated fabrication using methods of material bonding or deposition. This fabrication 
method produces objects with geometry difficult to be created using the “traditional” 
machining methods of milling, turning, or drilling. Generally, files generated using standard 
computer aided design (CAD) software are used to produce the scaffolds. 
Other techniques. Stereolithography uses a laser and a photosensitive liquid polymer solution 
to fabricate scaffolds. Three dimensional printing has been employed to fabricate porous 
scaffolds by inkjet printing liquid blinder droplets onto particulate matter.  
3.3 Overview of strategies used to combine adult stem cells and scaffolds 
The following section reviews primary studies that investigated the potential of different 
combinations of cells and scaffolds to improve the cell therapy benefits for PD, HD, cerebral 
ischemia and TBI. Studies on hRPE cells in combination with gelatine-based scaffolds, a 
device that underwent a phase II clinical trial for the treatment of PD will also be described. 
Several strategies are now focusing on improving cell interactions with the biomaterials by 
modifying its surface using biological molecules, mainly derived from ECM, to better 
regulate grafted cell behaviour. After briefly describing the molecular mechanisms of cell- 
ECM molecule interactions and its effect on cell behaviour, we will present some studies 
using such “biomimetic scaffolds”. Finally, the PAMs developed in our laboratory, that 
constitute a more advanced approach combining a bioactive surface with the controlled 
delivery of a growth factor will be presented.  
3.3.1 Gel-based scaffolds and cell encapsulating technology 
By contributing to maintain brain’s integrity as well as by favouring the integration of host 
cells inside the marginal cavities, gel-based scaffolds, without cells, may be advantageous to 
repair the brain after an ischemic stroke (Yamashita et al., 2009). Moreover, differentiated 
iPS injected together with a fibrin glue under the dura mater enhanced the effect of these iPS 
injected alone, which led to a reduced infarct volume as well as to  functional recovery after 
an ischemic stroke; thereby underlining the importance of a support for the cells (Chen & 
Xiao, 2011).  
In the context of TBI, degradable collagen scaffolds did not reduce the lesion size nor did 
they improve functional recovery, unless if seeded with hMSCs (Lu et al., 2007). Indeed, 
four days after TBI, transplantation of a cylindrical collagen scaffold seeded with hMSCs in 
the lesion cavity induced a reduction in the lesion volume, together with an improved 
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spatial learning and sensorimotor function of the animals. Recently, the same team reported 
that delayed transplantation of these complexes (7 days after TBI) further enhanced spatial 
learning and sensorimotor function, and induced angiogenesis in the injured cortex as well 
as transcallosal fiber length (Qu et al., 2009; Xiong et al., 2009). In experimental models of 
TBI, MSCs are usually injected adjacent to the lesion within the parenchyma to avoid 
injection within the lesion cavity. An advantage of this gel-based strategy was the possible 
use of 3 fold more MSCs compared to parenchymal injection, therefore increasing the 
regenerative potential. However, the major limitation was the need for open-surgery to 
implant the device. This issue may potentially be addressed using an in situ gelling process 
(Perale et al., 2011), even if the possible expansion and ensuing damage to the brain 
parenchyma of the solidifying gel has to be taken in consideration. Nevertheless, all these 
studies demonstrate the benefits of a 3D support which are probably improving cell 
survival, even if the underlying mechanisms are still not always fully understood. 
3.3.2 Cell adhesion on particulate scaffolds 
As previously described, the major problems encountered when grafting chromaffin cells in 
the context of PD was the poor cell survival and the absence of long term effects in vivo 
(Drucker-Colin & Verdugo-Diaz, 2004). Two studies gave the proof of concept that 
particulate scaffolds may enhance survival of cells adhered onto collagen-coated dextran 
(Cytodex 3®) or glass bead microcarriers into the brain of hemi-parkinsonian rats. The 
pivotal finding of these studies is that adult rat adrenal chromaffin cells implanted in the 
brain after attachment to microcarriers retain their ability for a prolonged period (8-12 
months) to correct a striatal dopamine deficit as judged by their efficacy in reducing 
apomorphine-induced rotation (Cherksey et al., 1996; Borlongan et al., 1998). Even if the 
underlying mechanisms were not studied, it is noteworthy that no inflammation was 
detected when implanted into the striatum. During the same period, these scaffolds were 
used for transplanting human FVM cells in similar rat model of PD (Saporta et al., 1997) and 
the Cytodex® microcarriers allowed an increased cell survival without immunosuppression. 
This effect was thought to result from the presence of a protective astrocytic cloak around 
the cell/microcarrier complexes. These data were the first to demonstrate the need for cell 
attachment to a 3D complex to improve grafted cell survival, and it also underlined the 
immunomodulatory benefits that may be gained from the use of a tissue engineering 
strategy. 
A similar strategy combines cultured hRPE cells attached to biocompatible, non 
biodegradable cross-linked porcine gelatine microcarriers, with a mean diameter of 100 µm. 
Several preliminary studies in parkinsonian rat models (unilateral and bilateral lesions) 
proved the efficacy of these grafted complexes, named  Spheramine® (Watts et al., 2003). An 
increased survival of hRPE cells, without immunosuppression, and long term functional 
improvements were observed, although chronic inflammation was reported at later time-
points (5 months) (Flores et al., 2007). These microcarriers have also been implanted in the 
brain of hemi-parkinsonian monkeys and resulted in long term cell survival and functional 
improvements at 18 months (Doudet et al., 2004). As expected, hRPE cells unattached to 
microcarriers did not survive well in the brain, and did not produce a lasting therapeutic 
effect in various PD animal models. These encouraging results led to an open-label clinical 
study that included 6 patients with advanced PD receiving 325,000 hRPE cells attached to 
microcarriers and demonstrated a good tolerability to Spheramine®. Moreover, at 6 months 
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post-operation, the mean UPDRS-M (off) score improved to 34 % from the pre-operation 
baseline. Half of the patients also demonstrated a reduced Dyskinesia Rating Scale scores 
(Bakay et al., 2004). The success of this strategy finally led to a phase II double-blind, 
randomized, multicenter, placebo-controlled (sham surgery) study to evaluate safety, 
tolerability, and efficacy of Spheramine® implanted bilaterally into the postcommissural 
putamen of patients with advanced PD, even if the mechanisms underlying the improved 
survival of hRPE cells upon attachment to gelatin are not yet well elucidated (Stover & 
Watts, 2008). Unfortunately, preliminary results of the phase II clinical trial seem to indicate 
that the study failed to demonstrate the efficacy of Spheramine® beyond a remarkable 
placebo effect. A reason for that may be the lack of long term survival of the cells in the 
human brain, as only around 0.036 % of cells survival was observed in the brain of a patient 
who died 6 months after surgery (Farag et al., 2009). 
Adult rat choroid plexus cells have the potential to secrete a wide range of growth factors, 
and have been used as candidate cells for HD cell therapy (Borlongan et al., 2008). In this 
study, choroid plexus cells were encapsulated in alginate beads to improve cell viability and 
to prevent host rejection. Transplantation of these cells into rat striatum resulted in an 
encouraging neuroprotection when a QA lesion was performed 3 days after cell 
transplantation, even if no evidence was provided concerning the specific sparing of 
GABAergic medium spiny projection neurons, especially sensitive to degeneration in the 
context of HD. 
3.3.3 Molecular mechanisms of cell adhesion to scaffolds 
The ECM contains adherent glycoproteins, glycosaminoglycans and ions. ECM proteins, 
such as collagen, FN, LM, tenascin and proteoglycans, interact with each other forming a 
supportive scaffold for the cells within the tissue (see for review (Bosman & Stamenkovic, 
2003)). Composition and proportion of its constituents vary depending on the type of tissue, 
thereby giving different mechanical, chemical or signalling cues to the surrounding cells. 
We will here focus on FN and LM because of their astonishing variety of effects on cells as 
well as because of their wide use for brain tissue engineering applications. FN and LM 
structures have been described a few decades ago and are constituted of an assembly of 
large polypeptides, all of them having specific interaction sites with other ECM molecules or 
cell surfaces (Hynes & Yamada, 1982; Engvall & Wewer, 1996; Powell & Kleinman, 1997). 
LM and FN interact with cells via the integrin family of receptors, therefore allowing cell 
attachment to the matrix and further signal transduction. Integrins are a family of proteins 
constituted of an ǂ subunit and a ǃ subunit which assemble into distinct integrin receptors 
having specific binding affinities with ECM molecules (Barczyk et al., 2009). These 
interactions result in highly complex downstream signalling pathways that originate at the 
focal adhesion sites, where a variety of proteins (e.g. Ilk, Fak, Src) interact with the integrin 
tails on their cytoplasmic ends, thereby regulating cell survival, proliferation and 
differentiation (Hynes, 2002; Chen, 2010). 
Potential roles of ECM molecules for brain repair are now widely admitted. Endogenous 
levels of FN and LM increase in a TBI context in vivo, thereby suggesting a reparative role of 
these molecules (Tate et al., 2007). Tissue repair benefits have also been obtained by 
transplanting LM-based hyaluronic gel scaffolds, without cells, in a rat model of cortical 
lesion (Hou et al., 2005). A recent study demonstrated an enhanced survival in vitro of 
human MSCs within a PEG hydrogel modified with RGD peptides, a motif involved in 
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ECM-cell interactions. In this study, RGD peptides attached to the scaffold provided the 
required adhesion sites to maintain MSC survival, while soluble peptides resulted in a 
strong decrease of cell viability. Noteworthy, the presence of a glycine spacer between the 
RGD peptides and the gel further improved MSC survival, therefore underlining the 
importance of the presentation context of the peptide within the gel (Salinas & Anseth, 
2008). Another team described the effect of FN and LM-derived peptides (RGDSP and 
IKVAV, respectively) using a PEG-hydrogel array to screen the effect of these ECM 
molecules on hMSCs viability. Their strategy allowed to also analyse the consequences of 
the hydrogel used, for example, the combination of the IKVAV peptides with degradable 
gels resulted in decreased sustained viability compared to non-degradable gels 
(Jongpaiboonkit et al., 2008). A recent study described the single-cell encapsulation of 
hMSCs in FN- and fibrinogen-containing hydrogel capsules that rescue the cells from 
apoptosis induced by loss of anchorage, while providing an increased cell metabolic activity 
in culture. Effects that were certainly mediated via the MAPK/ERK signalling cascade and 
upstream integrin/ECM molecule interactions (Karoubi et al., 2009). Using a subpopulation 
of hMSCs, we recently showed in a rat model of global ischemia, that marrow-isolated adult 
multilineage inducible (MIAMI) cells (D'Ippolito et al., 2004) adhered onto PLGA 
microcarriers with a FN biomimetic surface enhanced the neuroprotection effect observed 
with the cells alone (Garbayo et al., 2011). This effect may be attributed to an increased 
survival of the cells on these carriers, or the increased production of neuroprotective 
mediators by these cells or both.  
ECM molecules may also affect proliferation as well as life span of cells, this being the 
rationale for expanding MSCs on ECM molecules in several in vitro protocols (see for 
example (D'Ippolito et al., 2004; Matsubara et al., 2004)). Modification of PLCL (poly(L-lactic 
acid)-co-poly-(ε-caprolactone)) nanofibrous scaffolds with collagen I resulted in an increased 
proliferation of human MSCs and neuronal differentiation after exposure to an induction 
media, compared to standard PLCL scaffolds (Prabhakaran et al., 2009). The benefits of 
collagen I was assumed to result from its high cell adhesion properties, thought to be 
required to ensure a proper neuronal differentiation. In our laboratory, we observed an 
increased proliferation of the human stromal MIAMI cells expanded on FN compared to 
standard culture substrates (Delcroix et al., 2011). Extensive crosstalk takes place between 
integrin and growth factor receptor signalling pathways to stimulate progression through 
the G1 phase of the cell cycle, as mitogenic signalling may be weak and transient in the 
absence of integrin-mediated cell adhesion for cells with an anchorage dependent growth, 
such as MSCs (see (Danen & Yamada, 2001) for review).  
Neural precursor differentiation, by enhancing neurite outgrowth in vitro or in vivo is 
certainly one of the first and most studied effects of LM and its derived bioactive peptides 
(Rogers et al., 1983; Grimpe et al., 2002). Accumulating evidence support a bioactive 
signalling role of LM in the morphological and molecular induction of MSCs toward a 
neuronal lineage (Qian & Saltzman, 2004; Ho et al., 2006; Delcroix et al., 2011). In our 
laboratory, the enhanced expression of ǃ3-Tubulin and NFM when human mesenchymal 
stromal MIAMI cells were differentiated on a LM substrate was also accompanied with an 
increased cell length and a decreased proliferation rate (Delcroix et al., 2011). In this regard, 
a study reported the increased length of neurite-like extensions of MSCs, when incorporated 
within a collagen gel containing FN and LM, an effect at least partly mediated via the FAK 
pathway (Lee et al., 2011). Specific fragments of LM, e.g. the peptides IKVAV & YIGSR play 
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crucial signalling roles in neurite outgrowth and cell adhesion. Accordingly, studies also 
aim at functionalizing scaffolds with similar peptide fragments to reproduce the effect of the 
native ECM molecules, but also to isolate one of its specific effects (Powell & Kleinman, 
1997; Orive et al., 2009). Some observations of how ECM components control MSC 
behaviour are summarized in Table 3. 
 
Effects
ECM component or 
derived peptides
Observations References
RGDSP & IKVAV
PEG-hydrogel                                                                                                                                        
Both pept ides improved hMSCs survival                                                                                               
Combinat ion of IKVAV with degradable gels decreased the benef its compared to non-degradable 
ge ls
Jongpaiboonkit, King et al. 2008
FN
FN substrate                                                                                                                                         
Increased proliferation of MIAMI cells in vit ro
Delcroix, Garbayo et  al. 2011
LM substrate                                                                                                                                         
Induction of nest in expression by MSCs in vitro 
Ho, Yu et al. 2006
LM substrate                                                                                                                                         
Morphological changes in hMSCs during neuronal dif ferent iat ion in vitro                                               
Increased percentage of cells with secondary and tert iary branching on LM vs  FN or PDL 
Qian and Saltzman 2004
LM substrate                                                                                                                                         
Increased cell length and expression of neuronal proteins (β3-Tubulin and NFM) during 
differentiation of MIAMI cells in vit ro vs  FN  or glass
Delcroix, Garbayo et  al. 2011
Abbreviations: ECM: extracellular matrix molecules; FN: fibronectin; LM: laminin; MIAMI: marrow isolated adult multilineage inducible; MSC: mesenchymal stem cell; NFM: 
neurofilament medium; PDL: poly-D-lysine; PEG: polyethyleneglycol; PLCL: poly(L-lactic acid)-co-poly-(e-caprolactone).  
Prabhakaran, Venugopal et al.  2009
RGD Salinas and Anseth 2008
Lee, Yu et al. 2011
PEG hydrogel                                                                                                                                        
RGD improved hMSCs survival in vitro
Improvement enhanced with the use of  a g lycine spacer between RGD and the gel
Sing le-cell encapsulation of hMSCs in FN- or fibrinogen-containing hydrogel capsules  
Enhanced survival of cells + increased cell metabolic activity in  vitro 
Validation of  the concept in vivo (uninjured hindlimb model in rats)                                                       
PLCL/collagen I nanof ibrous scaffolds                                                                                                  
Increased proliferation of hMSCs vs  standard PLCL scaffolds 
Effect due to adequate cell adhesion propert ies of collagen I
Allow neuronal d ifferentiation of hMSCs when exposed to  the appropriate inducers
Collagen gel enriched with  FN and LM
Increased neurite length of MSCs incorporated within the gel
Effect mediated via  the FAK pathway
LMNeuronal differentiation
Collagen I
Karoubi, Ormiston et al. 2009
Proliferation
Survival
FN & fibrinogen
 
Table 3. Control of MSC behaviour by ECM components 
3.3.4 The pharmacologically active microcarriers (PAMs): a tool to combine the 
biomimetic approach and the controlled release of a growth factor 
In addition to the biomimetic approach, another way to improve the efficiency of cell grafts 
is to deliver a growth factor by the transplanted scaffolds, further affecting the fate of both 
transplanted and host cells. Interestingly, the potential of microsphere-hydrogel scaffolds to 
deliver 2 growth factors at specific rates has been described (Burdick et al., 2006), but has not 
yet led to in vivo studies. For reviews, see (Tatard et al., 2005; Delcroix, Schiller et al., 2010). 
Our group has formulated PLGA microspheres which deliver therapeutic proteins in a 
sustained and controlled manner. The use of these growth factor delivery vectors for 
neuroprotection or for the repair of the nigro-striatal dopaminergic system has been 
successfully validated in animal models of AD or of PD, respectively (Pean et al., 2000; 
Jollivet et al., 2004; Menei et al., 2005). In this sense, we developed the PAMs that combine 
these two approaches and may be easily injected in the desired tissue (Figure 1). These 
PAMs are biodegradable and biocompatible PLGA microspheres conveying cells on their 
surface, therefore providing an adequate 3D microenvironment in vivo. Moreover, the 
controlled delivery of a trophic factor in combination with a biomimetic surface act 
synergistically to stimulate the survival and/or differentiation of the grafted cells toward a 
specific phenotype, therefore enhancing their engraftment after their complete degradation 
(Tatard et al., 2005). Finally, it should be noted that the delivered molecule may also affect 
the host microenvironment allowing the integration of the grafted cells and/or stimulating 
the lesioned brain repair capacities. 
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Fig. 1. A) Schematic representation of PAMs. These PAMs are PLGA microspheres with a 
biomimetic surface that convey cells and release a growth factor in a controlled manner. B) 
Scanning electron microscopy image of PAMs conveying MIAMI cells on their surface 
The proof of concept of this unique and simple device of cell and protein-delivery in 
neuroprotection and tissue repair for the treatment of neurological disorders has first been 
validated in a PD rat model using a neuronal cell line (PC12 cells) transported by nerve 
growth factor (NGF)-releasing PAMs. (Tatard et al., 2004). The efficacy of PAMs for cell 
therapy of PD in a clinical paradigm was then demonstrated using GDNF-releasing PAMs, 
conveying a small number of embryonic ventral mesencephalon dopaminergic cells (Tatard 
et al., 2007). We next implemented the PAMs transporting MIAMI cells for PD adult stem 
cell therapy. MIAMI cells, may differentiate toward neuronal-like cells in a neurotrophin 3 
(NT3) dependent manner (Tatard et al., 2007), especially when pre-treated with EGF and 
bFGF (Delcroix, Curtis et al., 2010). Moreover, a LM surface enhances the neuronal 
differentiation (Delcroix et al., 2011). We designed PAMs made of 60 µm PLGA 
microspheres encapsulating NT3 and covered with a LM biomimetic surface. After adhesion 
of dopaminergic-induced (DI)-MIAMI cells, the PAM/cell complexes were grafted in the 
partially dopaminergic-deafferented striatum of rats and led to a strong reduction of the 
amphetamine-induced rotational behaviour together with the protection/repair of the 
nigrostriatal pathway. These effects were correlated with the increased survival of DI-
MIAMI cells which differentiated towards dopaminergic-like cells and may also secrete 
growth factors (Delcroix et al., 2011). We thus showed that combining growth factors, cell 
adhesion molecules and an adapted 3D structure in the same polymeric scaffold allows the 
synthesis of an adaptable and very efficient system that can deliver stem cells and give them 
appropriate cues allowing better stem cell survival, differentiation and integration into the 
host tissues after implantation. After deeper characterization of the underlying mechanisms, 
this tissue engineering strategy may ultimately set the ground for pre-clinical studies with 
non-human primates to increase the efficiency of MSC therapy of the brain.  
4. Unanswered questions in tissue engineering for targeting CNS disorders 
using conventional tissue culture and animal models 
Although brain tissue engineering has shown a certain level of therapeutic benefits, there 
are still many unanswered questions and concerns that need to be addressed. For instance, 
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one general problem found in cell therapy is the difficulty to reproduce results between 
laboratories. Differences on the source, method of preparation, differentiation status and 
age of the stem cells used may be the cause. Moreover, with the current workflow it takes 
a long time to select an effective stem cell strategy to translate into clinical studies. The 
main steps to follow include the selection of the source of cells (MSC, NSC, ESC, iPS), the 
choice of the culture media, the state of stem cell cycle (undifferentiated vs differentiated), 
the mode of culture, the form of growth (neurosphere vs monolayer for instance), the study 
of substrate variations (FN, LN, matrigel among others) and the use of different animal 
models to test each therapeutic variation. Moreover, very little is known about the exact 
mechanisms by which stem cells may repair damaged tissues. It is not yet totally 
understood if stem cells may directly replace lost cells via their differentiation potential or 
if the beneficial effect could be due to their paracrine secretions or their immune 
regulatory functions, or if it is due to a combination of these effects. An additional and 
very troublesome problem is the difficulty to track the location and activity of stem cells 
once they are grafted into the animal. Several strategies have been proposed to follow the 
grafted cells in vivo. One of the most commonly used is to label the cells with fluorescent 
markers like quantum dots, organic dyes or fluorescent proteins among others. Other 
authors have grafted sex mismatched stem cells to identify them by fluorescent in situ 
hibridation (FISH) on the X and Y chromosomes. The injection of human cells into rodent 
animals or vice versa to use species-specific antibodies for its identification is another 
approach.  
In general, it is difficult to understand stem cell mechanisms of action and fate using 
conventional tissue culture or animal models due to the limitations of both systems. In vitro 
models are a good high throughput screening tool but they do not realistically mimic the in 
vivo situation. Moreover, the 3D integration of grafted cells into the host tissue cannot be 
studied using tissue culture models. On the other hand, it is clear that animal models are 
essential in proof-of-concept principle experiments and in establishing the preclinical safety 
and efficacy data required before human clinical trials. However, most of them are 
expensive, laborious and time consuming to be useful as screening tests. Generally, it can be 
stated that as a system becomes more complex, the throughput in terms of screening 
capacity decreases (Sundstrom et al., 2005). Moreover, the real-time monitoring of grafted 
cells using animal models is not easy. A screening platform in-between in vitro and in vivo 
models is required to improve understanding of stem cells. A possible option would be the 
use of brain organotypic slice culture for optimization of CNS cell therapies. These 
organotypic cultures mimic in vivo models of brain diseases better than cell cultures, they 
are cost-effective and easier to optimize, use and manipulate than rodent and primate CNS 
disease models. The usefulness of brain organotypic slices in CNS research as well as in the 
drug discovery process has been increasing in recent years and will be discussed in the next 
section. 
5. Organotypic 3D culture models: novel platforms for optimization of CNS 
cell therapy and tissue engineering  
Since their introduction, organotypic cultures of rat brain slices have become a useful tool to 
study drug effects. Brain organotypic slices are ex-vivo cultures that bridge the gap between 
in vitro and in vivo models. Slices are easy to prepare and they preserve the tissue 
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architecture of the brain regions that they originated from, allowing interaction of multiple 
cell types like neurons, astrocytes and microglia and maintaining neuronal activities. This 
3D environment has tremendous importance to evaluate the efficacy of tissue engineering 
approaches since most of the cells require cues from a truly 3D environment to form 
relevant physiological tissue structures in vitro. This 3D provides external mechanical inputs 
and cell adhesion parameters, which affects intracellular signalling. Importantly, these slices 
permit direct treatment or injection of drugs, virus, cells, microscaffolds... making them 
ideal for screening (Cho et al., 2007). 
5.1 Preparation of organotypic cultures of CNS tissue 
Organotypic brain slice culture was developed by inspiration on explant cultures techniques 
of various anatomical origins. Since then, several methods have been developed to prepare 
and maintain slices alive in long-term culture. The roller-tube technique based on the use of 
roller tubes was first described in 1981 (Gahwiler, 1981). However, most studies now use the 
membrane interface method described in 1991 (Stoppini et al., 1991) which provides an 
easier access to the slice culture. The principle of the membrane interface method is to 
maintain brain slices on a porous membrane filter at the interface between medium and a 
humidified atmosphere. The medium provides adequate nutrition to tissues through the 
membrane via capillary action. Rats and mice are the most common donor sources, but also 
rabbits, pigs and human fetuses have been used. Most organotypic brain slice cultures have 
been derived from neonatal (P0-P10) animals, but recently also adolescent or adult rats have 
been used and even human postmortem brain tissue slices have been kept alive for a few 
weeks in culture (Noraberg et al., 2005). Brain slices are relatively easy to prepare (Figure 2).  
 
 
Fig. 2. Organotypic preparation; 7 to 11 days old rats are commonly used to prepare brain 
organotypic cultures. First the brain is dissected free of skull. Second, slicing is performed 
with a vibrating microtome. Finally, slices are maintained in cultured using the membrane 
interface method. Representative bright field images of hippocampal and nigrostriatal 
organotypics are shown in the figure 
Briefly, the brain is dissected free of the skull and placed into a saline solution whose 
composition resembles that of the cerebro-spinal fluid and is thus often referred to as 
artificial cerebro-spinal fluid (ACSF). Slicing is performed with a vibrating microtome at 
high amplitude and very slow speed. Slice thickness varies according to specimen and the 
type of experiment, from 150 to 400 μm (Lossi et al., 2009). Over the years, slice culture 
systems have been successfully established from a variety of brain regions including 
hippocampus (far more frequently), striatum, cortex, spinal cord and cerebellum. 
Furthermore, a number of tissue slice co-cultures have been developed, which allow the 
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assessment of inter-neural responses across brain regions. Moreover, when organotypic 
slices are exposed to certain toxic conditions (oxygen-glucose deprivation, neurotoxins, 
glutamate-mediated excitotoxicity) they develop many pathophysiological features found in 
brain disorders and consequently, brain organotypic slices can be used as ex-vivo models of 
CNS diseases. Nowadays, organotypic models for global cerebral ischemia, ischemic stroke, 
Alzheimer’s disease, PD, HD, TBI, epilepisa and amyotrophic lateral sclerosis have been 
described (For review see (Noraberg et al., 2005; Sundstrom et al., 2005; Cho et al., 2007; 
Cimarosti & Henley, 2008; Lossi et al., 2009)). Among them, hippocampal organotypic slices 
exposed to oxygen-glucose deprivation, a model for global cerebral ischemia is the most 
commonly used. 
5.2 Applications 
Organotypic slices have been commonly used as models to investigate mechanism and 
treatment strategies for neurodegenerative disorders. Interestingly, the utility of brain slices 
to test CNS cell therapy efficacy has recently started to be investigated. Organotypic cultures 
are a very useful tool for screening of candidate stem cells for a specific pathology. They also 
could be used to track survival, differentiation, proliferation and migration of the 
transplanted cells with or without microscaffolds or to study graft and host interactions 
(Figure 3). Stem cell mechanisms of neuroprotection or paracrine secretions of MSCs could 
be also studied using brain slices. Charriere et al.,(Charriere et al. 2010) analyzed the 
interactions between bone marrow stromal cells and hippocampal slice cultures to clarify 
putative cross-interactions between MSCs and the CNS that could explain the molecular 
mechanism of stem cells. The dopaminergic differentiation of ES in a PD organotypic model 
and the effect of morphogenetic proteins such as LM on the differentiation of the cells has 
also been studied (Kearns et al., 2006). It was also shown that olfactory ensheathing cells 
(OEC) when co-cultured with the auditory brain stem slice culture not only promoted 
neurite outgrowth from the cochlear nucleus region of the brain stem slice but also 
supported the OEC indicating positive interactions between both  (Jiao et al. 2010). Recently, 
our group examined the potential of MIAMI cells injected into the hippocampus to prevent 
neuronal damage induced by global ischemia using rat hippocampal slices exposed to 
oxygen-glucose deprivation. We showed that MIAMI cells prevented neuronal damage. 
MIAMI cell therapeutic value was significantly increased when delivering the cells 
complexed with FN-coated biomimetic microcarriers probably by increasing stem cell 
survival and paracrine secretion of pro-survival and/or anti-inflammatory molecules as 
concluded from survival, differentiation and gene expression analysis (Garbayo et al., 2011). 
Furthermore, brain organotypic slices can be used to perform tissue biocompatiblity studies 
of scaffolds prepared for brain tissue engineering application and to determine how changes 
in the composition or in the functionalization of the scaffold could compromise their brain 
biocompatibility. In this context, Kristensen et al., have used organotypic brain slice cultures 
to assess silicon-based arrays biocompatibility (Kristensen et al., 2001). Other exciting 
application could be to use them to determine what scaffold composition best promotes 
proper adhesion and proliferation of the stem cells. Recently, in various pathologies it has 
been reported that multiple growth factor delivery is more effective than single growth 
factor administration since it mimics better the natural microenvironments of tissue 
formation and repair (Richardson et al., 2001; Barrientos et al., 2008). The difficulties of this 
approach are principally to find the optimised growth factor ratio, each factor at a 
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physiological dose and in a specific spatiotemporal pattern. Brain organotypic slices could 
be used to determine proper growth factor cocktail for a specific brain damage and to 
control the relationship between growth factor concentration gradient and timing.  
 
 
Fig. 3. A) Nigrostriatal organotypic culture with GFP-hNSC forming complexes with PAMs 
injected into the striatum. GFP-hNSC cells were kindly provided by Dr Martinez-Serrano. B) 
Hippocampal organotypic culture with MIAMI cells forming complexes with PAMs injected 
into the CA1 hippocampus 
An innovative approach using modified organotypic slices derived from a transgenic, 
mutant, null, gain-of-function, loss-of function, knock-in, or knockout animals was recently 
proposed (Li & Loudon, 2008). They discuss the possibility of using modified organotypic 
slice cultures to understand how implanted cells interact with resident cellular matrix and 
injured residential cells to predict their in vivo behaviour (Li & Loudon, 2008). Organotypic 
cultures could also be used to evaluate how temporal expression levels of stem cell 
chemokine receptors can be quantitatively related with their migration capacity toward 
brain tumor- or lesion producing -signal ligand SDF-1. The foundation of this experimental 
platform is to establish a system that mimics in vivo properties, first to maintain stem cells in 
a quiescent state, and then induce stem cells to produce targeting molecule cytokine 
receptors and matrix remodeling enzymes. Li & Loudon showed that migration of stem cells 
was enhanced by an intermediate concentration of SDF-1 gradient but inhibited by higher 
concentrations, with no stimulation at low concentrations (Li & Loudon, 2008). 
5.3 Limitations of organotypics 
Organotypic slices are not without limitations. The most limiting features are: 1) currently 
brain slices are only produced from juvenile donor animals as it is known that young tissue 
has more neuronal plasticity and are more resistant than older tissue. Recent reports have 
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used older donors to prepare brain organotypic slices but although it is possible, a low yield 
was observed and slices remained viable for only 3 to 4 weeks. 2) Automation is a challenge 
since a skilled operator is required for the production of the slices. 3) Not all brain areas are 
amenable to culture being the most appropriate the regions with a lamellar structure that 
can be aligned parallel to the plan of slicing. 4) Organotypics do not have a functional 
vascular compartment (for review see Sundstrom et al., 2005). 
6. Conclusions  
Although the ideal brain scaffold that satisfies all the requirements does not exist yet, the 
past several years have seen considerable progress in this field of study. For instance, 
materials of many types have been used to create brain scaffolds capable of providing 
sustained delivery of signalling molecules and an adequate 3D support for transplanted 
cells, thereby increasing cell survival and even guiding cell differentiation and fate in vivo 
Scaffold surface characteristics have also been modified to better mimic the natural brain 
environment, to control cell attachment, growth and differentiation or for specific uses. A 
key-point to remember is that most regenerative technologies in the future will probably be 
combinatorial, including biocompatible scaffolds, stem cells and the various factors 
necessary for their survival and function. This might be especially true in order to 
implement iPS cells therapy in the future, to control their proliferation and differentiation 
potential. Continual progress in the design and fabrication of future scaffolds is required to 
improve current delivery platforms since there is a need for development of custom 
matrices either tailored for purpose, or for the individual patient. Recent developments in 
understanding the basic biology of brain tissue formation in physiological and pathologic 
conditions have resulted in an explosion in the numbers of bio-engineered and tissue 
engineering products that could be potential candidates for treating brain disorders. A 
major challenge for the pharmaceutical industry is to find useful tools for screening since a 
bottleneck exists between the number of compounds that are interesting and the relatively 
limited in vitro and in vivo existing methods. Animal models are still the main choice for 
such studies but over the past years, brain organotypic cultures have begun to emerge as 
useful tools for screening of new neuroprotective and neuroregenerative approaches. In the 
current chapter, the combination of adult stem cells with microscopic scaffolds has been 
revised. Recently, research on the application of nanotechnology in stem cell and tissue 
engineering research has gained much attention in the scientific community. A significant 
and exciting area of research is the use of nanoparticles to engineer different patterned 
topographies of scaffolds that mimic the ECM, to study their effects on stem cells.  
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